Seeking Alpha

Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005...

Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005 brain cancer drug. Shares -12.2% AH to $1.30.
Comments (2)
  • shel113
    , contributor
    Comments (12) | Send Message
     
    I sold of my Gern not long after they got out of the Stem Cell business. I mad a few dollars (but got hit when the stock price dived) but the reason for the purchase was buying into a leader in stem cell development. The company seemed to be going downhill and after holing on for some time it was time to hang it up. I am sorry that a company with what appeared to have cutting edge technology (which may yet be developed by Bio Time) has deteriorated to a point where it may cease to exist. I am considering Bio Time as an investment as I still believe that Geron's stem cell technology is very viable and has investment potential.
    3 Dec 2012, 05:08 PM Reply Like
  • Wilbe
    , contributor
    Comments (2) | Send Message
     
    This company must be poorly led because this is the second or third thing they have terminated. I have lost quite a bit on this poorly run company.
    3 Dec 2012, 08:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs